Very low enzyme activity was seen in mouse, rat and marmoset bone marrow, brain or skin; no activity could be detected in mammalian lung and heart.
In fact, increase of bone formation, leading to anti-osteoporotic and anti-osteoarthritis activity, could be obtained by induction of osteoblast activity, inhibition of osteoclast bone resorption, or both of these effects.
3′-F-fluoro-3′-deoxy L-thymidine (F-FLT) is used to detect and assess the haematopoietic bone marrow activity and could be helpful for the diagnosis of EMH [ 1].
Pre-planned saw blocks for both the patient bone and allograft bone could be alternatives.
Increased bone formation in the current study suggests that bone modeling of cortical bone could be increased by eldecalcitol treatment.
The additive effect of both compounds at inhibiting bone resorptive activity could then be explained by the sum of the effect of CS on the OPG and RANKL and the effect of one or both of these compounds on RANKL-independent mechanisms on osteoclastogenesis.
MMP-9 overexpression in the bone microenvironment could be an osteoclastic activator for bone resorption.
The bone-resorbing activity could not be explained solely by the presence of any of the cytokines known to stimulate bone resorption, including RANKL, PGE2, IL-1, TNF-α, IL-6, or IL-17.
The bone-resorbing activity could not be attributed solely to any of the known pro-inflammatory cytokines, well known to stimulate bone resorption, or to RANKL or prostaglandin E2 in SFs.
Due to proceeding bone healing, ramifications of trabecular bone could be seen between the implant particles.
